Analytical Data
-
Gene name
SLC35A1
-
简介
SLC35A1 is a key player in intracellular transport, acting as a transporter to transport CMP-sialic acid from the cytoplasm to the Golgi apparatus. As an antiporter, it exchanges CMP-sialic acid for CMP, maintaining cellular homeostasis. SLC35A1 Protein, Human (sf9, His, MBP, FLAG) is the recombinant human-derived SLC35A1 protein, expressed by sf9 insect cells , with N-MBP, C-Flag, N-8*His labeled tag.
- Application
-
Alternative Names
SLC35A1; CMP-sialic acid transporter; CMP-SA-Tr; CMP-Sia-Tr; Solute carrier family 35 member A1
-
Species
Human
-
Source
Baculovirus
-
Tag
N-MBP;C-Flag;N-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P78382
-
Expression Region
A2-V337
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC35A1, a member of the solute carrier family, encodes a protein that plays a crucial role in the transport of nucleotide sugars across the Golgi membrane, which is essential for glycosylation processes vital for protein and lipid modification. Mutations in SLC35A1 are associated with congenital disorders of glycosylation (CDG), highlighting its importance in maintaining cellular functions and proper development. Research on recombinant SLC35A1 protein has gained momentum due to its potential implications in understanding the mechanisms underlying glycosylation disorders and developing therapeutic strategies. By studying the functional properties and transport mechanisms of this protein, scientists aim to elucidate its role in glycosylation pathways and the resulting impact on cellular health. Additionally, the generation of recombinant SLC35A1 provides a tool for exploring interactions with other glycosylation-related proteins and assessing the effects of various mutations on its functionality. This research not only enhances our understanding of SLC35A1's involvement in CDG but also contributes to broader insights into glycosylation processes that are critical for various biological functions, including cell signaling, immune response, and pathogen recognition. Through advanced techniques in protein expression and characterization, investigations into SLC35A1 seek to bridge the gap between genetic mutations and their phenotypic consequences, paving the way for potential diagnostic and therapeutic advancements in the field of metabolic disorders.
